Lavish windfall gains from biotechnological unicorns
LOW RISK for entreprises
-
Fragmentation
-
Internationalization
-
Capital Intensity
-
Profitability
-
Fragmentation
-
Internationalization
-
Capital Intensity
-
Profitability
- Medicine demand bolstered by growing middle classes in Emerging Markets and aging population as a whole
- Resilience of drug spending irrespective of economic cycle, coupled with huge public support for improving people’s healthcare needs
- High level of R&D expenditure well covered by strong cash generation amid the pressing need for Covid-19 vaccines to reach herd immunity worldwide
- mRNA technology close to being a game-changer for the sector, especially in oncology treatments
- Venture capitalists and public investors’ appetite for investing in (listed) biotechnology firms
- Supply-chain disruptions due to states’ pressure to ‘reshore’ drug production within Western countries
- Lengthy procedures for new drug approvals on top of stiff price regulations
- Generic drug makers plagued with lower profit margins and higher debt gearing than patented drug ones
- Limited production capacities making it difficult to meet urgent delivery needs of all Covid-19 vaccines worldwide
- Bargaining power of India and China regarding vaccine production and delivery
Key players
Country | Role | Sector risk |
---|---|---|
China |
#1 market by revenue |
A
Low risk |
United States |
#2 market by revenue |
B
Medium risk |
Switzerland |
#3 market by revenue |
A
Low risk |
India |
#4 market by revenue |
A
Low risk |
Germany |
#5 market by revenue |
A
Low risk |
LATEST NEWS ABOUT PHARMACEUTICALS
-
Global outlook for private debt & private equity: private(r) for longer?
High inflation and escalating interest rates have tempered enthusiasm in private markets.
What to Watch 18 April 2024
Markets and the Talion law, expectations for the Indian elections, and the depreciation of the renminbi still ‘under control’
Latin America : Shall we dance?
This time was different: Latin America’s post-pandemic paso doble with inflation and the exchange rate.